Results 101 to 110 of about 38,467 (231)

A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility [PDF]

, 1994
Marilyn Green Larach, A. Russell Localio, Gregory C. Allen, M. A. Denborough, F.R. ELLIS, Gerald A. Gronert, Richard F. Kaplan, Sheila M. Muldoon, Thomas E. Nelson, Helle Ørding, Henry Rosenberg, B. E. Waud, Denise J. Wedel   +12 more
openalex   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Permeabilised skeletal muscle reveals mitochondrial deficiency in malignant hyperthermia-susceptible individuals [PDF]

, 2019
Leon Chang, Catherine Daly, Dorota Miller, Paul D. Allen, John P. Boyle, Philip M. Hopkins, Marie‐Anne Shaw   +6 more
openalex   +1 more source

Therapeutic Potential of Resveratrol in Cancer and Neurodegenerative Disorders: A Current Review

BioFactors, Volume 52, Issue 1, January/February 2026.
Resveratrol induces the expressions of TP53, NRF2, and JDP2 axis in cancer cells to control ROS balance in mitochondria. The antioxidation responses were induced through SRIT1/3, HDAC, STAT3, TGFβ, and so on, to trigger the inflammation, and NFkB response to lead to the cell death of cancers or neuro‐damaged cells.
Kenly Wuputra, Chia‐Che Ku, Ying‐Chu Lin, Yi‐Chun Tsai, Deng‐Chyang Wu, Yukio Mitsui, Maki Satou, Yuuki Tanaka, Shigeo Saito, Kazunari K. Yokoyama   +9 more
wiley   +1 more source

Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia‐Induced Glycolysis by Targeting Hypoxia‐Inducible Factor‐1 Alpha and Downstream Metabolites

Cancer Medicine, Volume 15, Issue 1, January 2026.
The debate in the field of cancer immunotherapy is being changed as nanotechnology breaks the obstacle of cancer immune evasion, target delivery, and systemic toxicity. Esthetically advanced methods that are discussed in this review are nanovaccine, nanoparticle‐enabled checkpoint barrier, cytokine delivery, and T‐cell modulation techniques that ...
Daniel Ejim Uti, Wilson Achu Omang, Esther Ugo Alum, Inalegwu Bawa, Okechukwu Paul‐Chima Ugwu, Ayodeji Oluwafemi Idowu, Item Justin Atangwho, Godwin Eneji Egbung   +7 more
wiley   +1 more source

Malignant Hyperthermia with Rigidity Successfully Treated with Procainamide [PDF]

, 1973
William H. Noble, Daniel McKee, B. Gates
openalex   +1 more source

Novel Genetic Findings in Stuve‐Wiedemann Syndrome: A Case Report and Review of Literature

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Stuve‐Wiedemann Syndrome (SWS) is a rare autosomal recessive condition, first reported in 1971 by Stuve and Wiedemann. It is associated with pathogenic or likely pathogenic homozygous or compound heterozygous variants in the Leukemia Inhibitory Factor Receptor (LIFR) gene.
Khalid Hamasalih Hamasharef, Zana Baqi Najmadden, Rozhgar AKhailany, Muhammad Jabar Rashid, Kaiwan Hamakarim   +4 more
wiley   +1 more source

EGFR p.V774M/p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC‐ and Furmonertinib‐Based Treatment: A Case Report

Cancer Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Background Intrapleural perfusion hyperthermic chemotherapy (IPHC) can be used to select specific lung cancer cells of a certain genotype. Some genetic mutations, especially epidermal growth factor receptor (EGFR) mutations, are potential markers for EGFR or other targeted therapies. Here, we report a unique case of a patient with EGFR p.V774M/
Yanan Wang, Guanying Ren, Zizheng Song, Ling Hu, Weiqi Li, Xiaolei Wang   +5 more
wiley   +1 more source

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Graphical representation of STING‐activated nanomedicines is for effective treatment of triple‐negative breast cancer. Abstract Triple‐negative breast cancer (TNBC), marked by profound immunosuppressive complexity, poses a critical challenge in therapy due to the absence of hormone receptors in its phenotype, making it unavailable for conventional ...
Harshita Singhai, Taha Alqahtani, Humood Al Shmrany, Garima Gupta, Umesh Kumar Patil, Amirhossein Sahebkar, Prashant Kesharwani   +6 more
wiley   +1 more source

Nanotechnology in Skin Cancer Therapy: Recent Progress in Targeted Delivery

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 1, January 2026.
ABSTRACT Skin cancer, encompassing melanoma and non‐melanoma types, remains a significant public health concern globally. Conventional therapies—such as surgery, radiotherapy, chemotherapy, and immunotherapy—are constrained by poor skin penetration, systemic toxicity, and high recurrence rates.
Huang‐Ping Yu, Ching‐Yun Hsu, Jia‐You Fang, Zih‐Chan Lin   +3 more
wiley   +1 more source